Artivion, Inc. (NYSE:AORT) SVP Sells $145,698.85 in Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 5,335 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the completion of the sale, the senior vice president now directly owns 149,799 shares of the company’s stock, valued at approximately $4,091,010.69. This represents a 3.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Artivion Price Performance

Shares of AORT opened at $25.44 on Thursday. The company has a market capitalization of $1.07 billion, a P/E ratio of -1,272.00 and a beta of 1.75. Artivion, Inc. has a twelve month low of $18.38 and a twelve month high of $32.33. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The firm has a 50 day moving average of $29.68 and a 200 day moving average of $27.83.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Monday, February 24th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51). Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. The business had revenue of $97.31 million for the quarter, compared to the consensus estimate of $100.82 million. As a group, equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AORT has been the subject of a number of research reports. Needham & Company LLC decreased their price target on shares of Artivion from $34.00 to $32.00 and set a “buy” rating for the company in a research note on Tuesday. Oppenheimer raised their target price on Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. Stifel Nicolaus reduced their price target on Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, JMP Securities reissued a “market outperform” rating and set a $33.00 price objective on shares of Artivion in a research note on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $31.40.

Institutional Trading of Artivion

A number of institutional investors have recently made changes to their positions in AORT. Squarepoint Ops LLC raised its stake in Artivion by 30.8% during the 4th quarter. Squarepoint Ops LLC now owns 35,707 shares of the company’s stock valued at $1,021,000 after buying an additional 8,404 shares during the last quarter. Tidal Investments LLC increased its position in shares of Artivion by 14.5% during the 4th quarter. Tidal Investments LLC now owns 179,806 shares of the company’s stock valued at $5,141,000 after purchasing an additional 22,804 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Artivion in the 4th quarter worth approximately $64,000. Point72 Asset Management L.P. bought a new stake in Artivion during the fourth quarter valued at approximately $5,573,000. Finally, ProShare Advisors LLC raised its position in Artivion by 44.7% in the fourth quarter. ProShare Advisors LLC now owns 11,924 shares of the company’s stock worth $341,000 after acquiring an additional 3,683 shares during the period. Hedge funds and other institutional investors own 86.37% of the company’s stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.